May 16, 2007 by Brian LawlerCVT Readies Another DrugCVT files for marketing approval of another drug.
May 16, 2007 by Brian LawlerGPC's Next Cancer Drug?GPC Biotech prepares for its future as it awaits an FDA decision on its lead drug.
May 15, 2007 by Brian LawlerKing Fights for Its EmpireKing announces another good quarter of financial results.
May 14, 2007 by Brian LawlerDendreon Tries to Pick Up the PiecesDendreon lays out its preliminary plans following a negative FDA regulatory decision.
May 14, 2007 by Brian LawlerJust the Beginning for Flamel?Flamel releases first-quarter financial results
May 14, 2007 by Brian LawlerOnyx RocksOnyx Pharmaceuticals announces first-quarter financial results.
May 14, 2007 by Brian LawlerMylan Goes on a Drug BingeGeneric drugmaker Mylan makes a hefty acquisition
May 14, 2007 by Brian LawlerSour Results for NektarNektar Therapeutics announces its first-quarter financial results and plans for the future.
May 9, 2007 by Brian LawlerDiagnosing Dendreon PostmortemThe FDA issues an approvable letter for Dendreon's top compound.
May 9, 2007 by Brian LawlerWhere Is Momenta's Momentum?Momenta awaits an FDA regulatory decision and announces quarterly financial results.
May 8, 2007 by Brian LawlerNo Earnings at EncysiveEncysive releases dour first-quarter financial results.
May 8, 2007 by Brian LawlerUnstoppable CelgeneCelgene continues its strong financial results as Revlimid sales grow.
May 8, 2007 by Brian LawlerNeurocrine Is Waking UpNeurocrine releases its first-quarter financial results.
May 7, 2007 by Brian LawlerSanofi Rolls the Lawsuit DiceDon't be fooled by rosy results; litigation risk still looms here.
May 7, 2007 by Brian LawlerViroPharma VictoriousA strong first quarter helps the pharmaceutical storm into 2007.
May 7, 2007 by Brian LawlerWill InterMune Get a Vaccine?A treatment for hepatitis C might cushion the losses from a fibrosis treatment.
May 7, 2007 by Brian LawlerExelixis? Excellent!Promising test results for a pending cancer drug thrill investors.
May 3, 2007 by Brian LawlerPanacos Reveals the PlanPanacos details the plan for clinical testing of its lead compound.
